Skip to main
AORT

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artivion is well-positioned for growth due to its strong product portfolio and global presence, with a focus on aortic solutions for cardiac and vascular surgeons. While the company's non-North American revenue and tissue preservation services do present some risks, these are largely outweighed by the potential for growth through new product launches and international expansion. Despite temporary challenges that led to a recent guidance reduction, we believe Artivion's shares are undervalued compared to its peers, making it a positive investment opportunity.

Bears say

Artivion is facing challenges with their existing product, AMDS, due to HDE and IRB approval limitations and financial hurdles. While they have a strong pipeline and upcoming product launches, it is uncertain how successful these endeavors will be as they also face competition in the market. Additionally, new account onboarding has been hindered by the financial commitment required for their starter set, but management believes solutions are in place to address this issue.

Artivion (AORT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Artivion (AORT) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.